Moderna produces Covid-19 shot targeting variant discovered in SA

News

Moderna produces Covid-19 shot targeting variant discovered in SA

The US biotech is preparing for a clinical trial to gauge the effectiveness of the vaccine on 501.V2 strain

Hannah Kuchler

Moderna has become the first vaccine maker to produce a Covid-19 shot targeted at the virus variant discovered in SA. It will ship the doses to the US National Institutes of Health (NIH) for a clinical trial. 

The Boston-based biotech is taking a three-pronged strategy to address concerns that its vaccine, with several others, is less effective against the 501.V2 strain. 

The company has already started giving previous trial participants a half-dose booster of the existing shot to top up their immune response. It has now created a vaccine booster targeted at the variant, also at half a dose. US immunologist Anthony Fauci’s team at the NIH will begin testing it in phase one trial participants within weeks. ..

This article is reserved for Sunday Times Daily subscribers.
A subscription gives you full digital access to all Sunday Times Daily content.

Sunday Times Daily

Already subscribed? Simply sign in below.

Questions or problems?
Email helpdesk@timeslive.co.za or call 0860 52 52 00.